Corporate CEO Cal Hunter has been recruited by biotech startup Zuritech to launch what is to be the next breakthrough in cardiovascular care, a blockbuster drug that will lower medical costs and save millions of lives. New to the US market, Zuritech hits upon a formula that will generate billions in profits and destroy the competition in the process. When Cal uncovers irregularities in the clinical trials being conducted for FDA approval, he finds...